Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER-Negative PR-Negative HER2-Negative Breast Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT03750240
What this trial is testing

Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy

Who this might be right for
Breast CancerTriple Negative Breast Cancer
NYU Langone Health 2
Early research (Phase 1)Looking for participantsNCT07311993
What this trial is testing

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Cellectar Biosciences, Inc. 60
Testing effectiveness (Phase 2)Study completedNCT00733408
What this trial is testing

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast Cancer+3 more
University of Washington 59
Large-scale testing (Phase 3)Study completedNCT02425891
What this trial is testing

Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Who this might be right for
Triple Negative Breast Cancer
Hoffmann-La Roche 902
Testing effectiveness (Phase 2)Study completedNCT02048059
What this trial is testing

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Who this might be right for
Breast CancerBrain Metastases
Angiochem Inc 72
Testing effectiveness (Phase 2)Study completedNCT03316586
What this trial is testing

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 18
Early research (Phase 1)Active Not RecruitingNCT07038369
What this trial is testing

ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Who this might be right for
Advanced Solid TumorsBreast CancerBreast Carcinoma+24 more
Atavistik Bio, Inc 134
Testing effectiveness (Phase 2)Looking for participantsNCT05491083
What this trial is testing

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Who this might be right for
Advanced Solid TumorTriple Negative Breast Cancer
National University Hospital, Singapore 51
Testing effectiveness (Phase 2)Study completedNCT01031446
What this trial is testing

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07458113
What this trial is testing

Sac-TMT for Active TNBC Brain Metastases

Who this might be right for
Metastatic Triple Negative Breast Cancers
Yale University 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691
What this trial is testing

Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Not applicableTemporarily pausedNCT02993068
What this trial is testing

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Who this might be right for
BARD1 Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+12 more
M.D. Anderson Cancer Center 5,200
Early research (Phase 1)UnknownNCT02977468
What this trial is testing

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Eileen Connolly 15
Not applicableAvailableNCT01216124
What this trial is testing

Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients

Who this might be right for
Triple Negative Local Advanced Breast Cancer
Fudan University
Not applicableLooking for participantsNCT05877859
What this trial is testing

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Who this might be right for
Breast Cancer Triple NegativeBreast Cancer Stage IIBreast Cancer Stage III+1 more
Emory University 10
Not applicableLooking for participantsNCT07066189
What this trial is testing

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

Who this might be right for
Triple Negative Breast Cancer
Yale University 160
Large-scale testing (Phase 3)Looking for participantsNCT06393374
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Who this might be right for
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC 1,530
Not applicableUnknownNCT03756090
What this trial is testing

The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer

Who this might be right for
Breast CancerBreast DiseasesBreast Neoplasms
Zhejiang Cancer Hospital 100
Early research (Phase 1)Ended earlyNCT03579472
What this trial is testing

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
M.D. Anderson Cancer Center 38
Testing effectiveness (Phase 2)Study completedNCT01990209
What this trial is testing

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Who this might be right for
Metastatic Breast Cancer
SCRI Development Innovations, LLC 71
Next Page